ArticleMedicine2025
Construction of a comprehensive protein-protein interaction network to identify key genes associated with osteoarthritis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This research aims to identify key genes and therapeutic targets for osteoarthritis (OA) through bioinformatics, addressing the condition's significant impact on patients' lives and healthcare systems. Current treatments are often ineffective, underscoring the need for a deeper understanding of OA's molecular mechanisms. We investigate cell death mechanisms like pyroptosis and autophagy in OA, using gene expression omnibus datasets to identify differentially expressed genes and develop a protein-protein interaction network highlighting 7 critical genes, including gap junction alpha-1 protein (GJA1) as a potential biomarker. We also created a diagnostic model validated through receiver operating characteristic analysis, which could enhance OA detection and improve patient outcomes. Experimental results from quantitative real-time polymerase chain reaction confirmed the downregulation of GJA1 in the OA group. Significant downregulation of GJA1 expression in patients diagnosed with OA was confirmed. GJA1 may function as a novel regulatory factor in the onset and progression of OA, with potential applications as a diagnostic biomarker for the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.